Richard Hart

WuXi Biologics provides a state of the art, single-source technology platform to expedite our customer’s biologic development projects from concept through to commercialization. WuXi Biologics vision: “Every biologic can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry.” Our focus is on understanding and delivering our customer's project milestones to realise the best possible value for our customers.

Leaf Expression Systems are a contract development and manufacturing business specialising in the expression and production of proteins, metabolites and complex natural products using a proprietary transient expression.

Providing business development support to companies serving the bio-pharmaceutical industry. Working with a wide range of organisations, including integrated R&D services, drug delivery, clinical services, trade association, fill & finish and biologics manufacturing companies.

Establishing the Business Development function of Stelis BioSource at Stelis Biopharma, to provide contract bioprocess development, scale-up and manufacturing solutions for Biologic Drug Substance and Drug Product. Located in Bangalore, India - a technology hub for pharmaceutical R&D and manufacturing.

Establishing a Regional Business Development function in Europe for Syngene - a leading global custom research and manufacturing organization based in Bangalore,India. Syngene supports R&D programs from lead generation through to clinical supplies. Integrated drug discovery and development services include capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

BioProcess International 2016 WINNER: Stratophase - Ranger Service Best Technology Application – Upstream User or supplier of an application that has demonstrated significant adoption, process improvements and documented results. I supported the market adoption of this break-through innovation in dynamic bio-process optimisation. The Ranger (TM) service enables real-time, on-line automated process optimisation, for example with cell culture feeding. Delivering faster development of more robust processes with reduced process risk and reduced COGs for real competitive advantage.

Capsugel - global leader in innovative dosage forms and solutions for the healthcare industry. Reporting to the SVP EMEA, with responsibility for growing the new product pipeline. Working closely with Sales, Marketing, Quality, R&D and Global Business Development to achieve the regional revenue and EBITDA plan. • Significantly strengthened new customer projects pipeline through targeted activity, resulting in over 250 projects under personal management • Developed a deeper and wider network with R&D and senior management teams within target customers. Led multi-disciplinary business teams to realise a surge of cross-selling opportunities to achieve strong growth in new projects. • Developed new relationships with leading pharmaceutical academic institutions, enhancing company influence and reputation.

Baxter BioPharma Solutions (BPS) provides contract development and manufacturing services to biopharmaceutical companies developing sterile injectable products. Responsible for identification and development of new business opportunities with clients based in Europe (and the US where the global customer has operations in the US). Full responsibility for negotiating and closing agreements for the provision of BPS services. • Developed relationships with new customers resulting in opportunities and signed business at the same time as broadening the global key account relationship with specific customers. • Led multi-disciplinary teams including Project Management, Legal Counsel and other specialists as required in structured customer negotiations to achieve business objectives. This leadership was praised by colleagues such as the experienced Head of Legal Counsel and other team members. • Signed supply agreements to a total contract value of $55M in my first three years.

Contract process development and cGMP manufacturing services to companies developing biologics for human therapeutic use. CMC built and opened its first manufacturing facility in February 2004. Reporting to the CEO, responsible for growing the contract development and manufacturing business in Europe. • Developed new internal processes for customer project and relationship management, leading to improved customer trust and reputation. • Contributed strongly to revenue growth from €5M to €32M over a four-year period, whilst increasing company credibility as a reliable contract bio-manufacturing partner.

Originally Covance Biotechnology Services Inc, a contract bio-manufacturing service provider with facilities in US and Europe. Led business development in Europe for contract services conducted in US and Europe. • Established first sales with European customers and negotiated contracts with values ranging from $900k to $3,5M. • Regularly presented at industry conferences to help grow the company visibility as rapidly as possible.